遺伝性乳がん・卵巣がん症候群治療の世界市場レポート 2025年

遺伝性乳がん・卵巣がん症候群治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.4％で91億9,000万米ドルに成長します。予測期間の成長は、人工知能の役割の拡大、遺伝カウンセリングへのアクセス拡大、標的療法の規制承認、個別化治療計画、研究における国際共同研究などに起因すると考えられます。予測期間の主な動向には、遺伝子編集技術、免疫療法の進歩、腫瘍学の技術的進歩、BRCA関連がんの免疫療法、包括的集学的治療などがあります。

予想される遺伝性疾患の増加は、今後数年間の遺伝性乳がん・卵巣がん症候群治療市場の成長を牽引するとみられます。新生児スクリーニングは、出生後に乳幼児の特定の健康状態を検査するもので、医療専門家が潜在的な健康問題が生じる前に特定のニーズを特定し対処することを可能にします。このスクリーニングにより、乳がんや卵巣がんの発症リスクが高い乳幼児を特定することができ、早期の予防対策が可能になります。2022年、テキサス州保健局は、新生児スクリーニング検体の受理数が4.3％増加し、2021年の729,347検体から2022年には761,000検体に増加したと報告しました。このうち約39万4,000人の乳児がスクリーニングを受け、2022年には1,130人がNBS疾患のいずれかに罹患しました。したがって、遺伝性疾患の急増は遺伝性乳がん・卵巣がん症候群治療市場の成長を促進する重要な要因です。

卵巣がんの有病率の上昇は、遺伝性乳がん・卵巣がん症候群治療市場の成長をさらに促進すると予想されます。卵巣の悪性腫瘍である卵巣がんは、長寿化、出産の遅れ、ライフスタイルの変化などの要因により有病率が増加しています。遺伝性乳がん・卵巣がん症候群（HBOC）は、乳がん、卵巣がん、その他のがんのリスクを高める遺伝的疾患であり、この動向に大きく寄与しています。世界卵巣がん連合の2022年2月の報告書によると、卵巣がんは2020年に世界で313,959人の女性に罹患し、この数は2020年から2040年の間に42％増加して445,721人になると予測されています。その結果、卵巣がんの有病率の増加が遺伝性乳がん・卵巣がん症候群治療市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界遺伝性乳がん・卵巣がん症候群治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の遺伝性乳がん・卵巣がん症候群治療市場：成長率分析
• 世界の遺伝性乳がん・卵巣がん症候群治療市場の実績：規模と成長, 2019-2024
• 世界の遺伝性乳がん・卵巣がん症候群治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界遺伝性乳がん・卵巣がん症候群治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の遺伝性乳がん・卵巣がん症候群治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン療法
• 化学予防
• 遺伝カウンセリング
• 薬
• その他の治療法
• 世界の遺伝性乳がん・卵巣がん症候群治療市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子検査
• 磁気共鳴画像（MRI）
• マンモグラフィー
• その他の診断
• 世界の遺伝性乳がん・卵巣がん症候群治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の遺伝性乳がん・卵巣がん症候群治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の遺伝性乳がん・卵巣がん症候群治療市場ホルモン療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的エストロゲン受容体モジュレーター（SERM）
• アロマターゼ阻害剤
• 世界の遺伝性乳がん・卵巣がん症候群治療市場化学予防のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タモキシフェン
• ラロキシフェン
• 世界の遺伝性乳がん・卵巣がん症候群治療市場遺伝カウンセリングのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リスクアセスメント
• 家族計画ガイダンス
• 世界の遺伝性乳がん・卵巣がん症候群治療市場、医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 免疫チェックポイント阻害剤
• 世界の遺伝性乳がん・卵巣がん症候群治療市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予防手術
• 監視戦略

第7章 地域別・国別分析

• 世界の遺伝性乳がん・卵巣がん症候群治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の遺伝性乳がん・卵巣がん症候群治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 遺伝性乳がん・卵巣がん症候群治療市場：競合情勢
• 遺伝性乳がん・卵巣がん症候群治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi-Aventis LLC
• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Co. Ltd.
• Vertex Pharmaceuticals Inc.
• Mercy Health
• Hikma Pharmaceuticals plc
• Amneal Pharmaceuticals LLC
• Lupin Limited
• Seagen Inc.
• LEO Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 遺伝性乳がん・卵巣がん症候群治療市場2029：新たな機会を提供する国
• 遺伝性乳がん・卵巣がん症候群治療市場2029：新たな機会を提供するセグメント
• 遺伝性乳がん・卵巣がん症候群治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Treatment for hereditary breast and ovarian cancer syndrome (HBO) refers to a comprehensive set of measures and medical strategies aimed at addressing the heightened risk of developing breast and ovarian cancers in individuals with a genetic predisposition to the syndrome. The objective of hereditary breast and ovarian cancer syndrome (HBO) treatment is to either prevent the onset of cancer or detect it at an early, more treatable stage.

The primary treatments for hereditary breast and ovarian cancer syndrome include hormonal therapy, chemoprevention, genetic counseling, medication, and other therapeutic approaches. Hormone replacement therapy, specifically estrogen-based and of a temporary nature, is targeted at alleviating individual acute symptoms in cases of hereditary breast and ovarian cancer (HBOC) syndrome, particularly in individuals with BRCA1 or BRCA2 mutations. Diagnosis involves genetic testing, magnetic resonance imaging (MRI), mammography, and other methods. Medications can be administered through various routes, including oral, parenteral, and others, with delivery facilitated by hospitals, specialty clinics, home care services, and other healthcare providers.

The hereditary breast and ovarian cancer syndrome market research report is one of a series of new reports from The Business Research Company that provides hereditary breast and ovarian cancer syndrome market statistics, including hereditary breast and ovarian cancer syndrome industry global market size, regional shares, competitors with a hereditary breast and ovarian cancer syndrome market share, detailed hereditary breast and ovarian cancer syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary breast and ovarian cancer syndrome industry. This hereditary breast and ovarian cancer syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary breast and ovarian cancer syndrome treatment market size has grown strongly in recent years. It will grow from $6.72 billion in 2024 to $7.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased awareness and screening, supportive government policies, patient advocacy and empowerment, collaboration in research.

The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $9.19 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the growing role of artificial intelligence, expanded access to genetic counseling, regulatory approvals for targeted therapies, personalized treatment plans, international collaborations in research. Major trends in the forecast period include gene editing technologies, advancements in immunotherapy, technological advances in oncology, immunotherapy for BRCA-related cancers, comprehensive multidisciplinary care.

The anticipated increase in genetic disorders is set to drive the growth of the hereditary breast and ovarian cancer syndrome treatment market in the coming years. Newborn screening, a post-birth examination for specific health conditions in infants, enables health professionals to identify and address specific needs before any potential health issues arise. This screening could identify infants at a higher risk of developing breast and ovarian cancer, allowing for early preventive measures. In 2022, the Texas Department of State Health Services reported a 4.3% increase in newborn screening specimens received, rising from 729,347 in 2021 to 761,000 in 2022. Of these, approximately 394,000 babies were screened, with 1,130 affected by one of the NBS disorders in 2022. Therefore, the surge in genetic disorders is a key factor propelling the growth of the hereditary breast and ovarian cancer syndrome treatment market.

The rising prevalence of ovarian cancer is expected to further fuel the growth of the hereditary breast and ovarian cancer syndrome treatment market. Ovarian cancer, a malignant tumor in the ovaries, has seen increased prevalence due to factors such as increased longevity, delayed childbearing, and changes in lifestyle. Hereditary Breast and Ovarian Cancer Syndrome (HBOC), a genetic condition elevating the risk of breast, ovarian, and other cancers, is a significant contributor to this trend. According to the World Ovarian Cancer Coalition's February 2022 report, ovarian cancer affected 313,959 women globally in 2020, and this number is projected to rise by 42% to 445,721 between 2020 and 2040. Consequently, the growing prevalence of ovarian cancer is a driving force behind the growth of the hereditary breast and ovarian cancer syndrome treatment market.

Major companies in the hereditary breast and ovarian cancer syndrome treatment market are adopting innovative treatment options, such as comprehensive risk tests, to enhance their services. A comprehensive risk assessment test is a tool designed to identify an individual's risk of developing a disorder or experiencing symptoms of a disease. Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched a groundbreaking comprehensive risk assessment test in February 2023. This test combines gene mutation testing for breast and ovarian cancers, assesses hereditary and non-hereditary risk factors, and calculates the GeneType risk score for both cancers. It targets women over 30 at a higher risk of breast and ovarian cancer in the general population.

In March 2023, Invitae Corporation, a US-based biotechnology company, entered into a partnership with Epic Systems Corporation to streamline the genetic testing process. This collaboration aims to integrate genetic information into standard workflows, facilitating enhanced personalized healthcare delivery within the Epic community. Epic Systems Corporation, a US-based platform provider, plays a crucial role in evaluating a patient's risk for hereditary cancer, including hereditary breast and ovarian cancer syndrome (HBOC).

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care

North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hereditary breast and ovarian cancer syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hereditary breast and ovarian cancer syndrome treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, surveillance, screening, prophylactic surgeries, chemoprevention, clinical trials, ongoing monitoring, family testing, and psychosocial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary breast and ovarian cancer syndrome treatment market also includes sales of lynparza, talazoparib, rucaparib, and niraparib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary breast and ovarian cancer syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary breast and ovarian cancer syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary breast and ovarian cancer syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Hormonal Therapy; Chemoprevention; Genetic Counselling; Medication; Other Treatments
• 2) By Diagnosis: Genetic Testing; Magnetic Resonance Imaging (MRI); Mammography; Other Diagnosis
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors
• 2) By Chemoprevention: Tamoxifen; Raloxifene
• 3) By Genetic Counselling: Risk Assessment; Family Planning Guidance
• 4) By Medication: Targeted Therapies; Immune Checkpoint Inhibitors
• 5) By Other Treatments: Preventive Surgery; Surveillance Strategies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck & Co.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Characteristics

3. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Trends And Strategies

4. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Growth Rate Analysis
• 5.4. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Total Addressable Market (TAM)

6. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Segmentation

• 6.1. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Therapy
• Chemoprevention
• Genetic Counselling
• Medication
• Other Treatments
• 6.2. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing
• Magnetic Resonance Imaging (MRI)
• Mammography
• Other Diagnosis
• 6.3. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.5. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Estrogen Receptor Modulators (SERMs)
• Aromatase Inhibitors
• 6.6. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Sub-Segmentation Of Chemoprevention, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tamoxifen
• Raloxifene
• 6.7. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Sub-Segmentation Of Genetic Counselling, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Risk Assessment
• Family Planning Guidance
• 6.8. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapies
• Immune Checkpoint Inhibitors
• 6.9. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Surgery
• Surveillance Strategies

7. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Regional And Country Analysis

• 7.1. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 8.1. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 9.1. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 9.2. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 10.1. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 11.1. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 11.2. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 12.1. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 13.1. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 14.1. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 14.2. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 15.1. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 15.2. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 16.1. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 17.1. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 18.1. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 19.1. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 20.1. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 21.1. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 21.2. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 22.1. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 23.1. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 23.2. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 24.1. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 24.2. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 25.1. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 25.2. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 26.1. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 26.2. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 27.1. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 28.1. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 28.2. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

• 29.1. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview
• 29.2. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Landscape And Company Profiles

• 30.1. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Landscape
• 30.2. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi-Aventis LLC
• 31.3. AstraZeneca plc
• 31.4. Abbott Laboratories
• 31.5. GlaxoSmithKline plc
• 31.6. Eli Lilly and Company
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Daiichi Sankyo Co. Ltd.
• 31.9. Vertex Pharmaceuticals Inc.
• 31.10. Mercy Health
• 31.11. Hikma Pharmaceuticals plc
• 31.12. Amneal Pharmaceuticals LLC
• 31.13. Lupin Limited
• 31.14. Seagen Inc.
• 31.15. LEO Pharma Inc.

32. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

34. Recent Developments In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

35. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Hereditary Breast and Ovarian Cancer Syndrome Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hereditary Breast and Ovarian Cancer Syndrome Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hereditary Breast and Ovarian Cancer Syndrome Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer